Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS): $1.94

0.12 (-5.83%)

POWR Rating

Component Grades








Add CHRS to Watchlist
Sign Up

Industry: Biotech




#87 of 339

in industry

CHRS Price/Volume Stats

Current price $1.94 52-week high $10.99
Prev. close $2.06 52-week low $1.43
Day low $1.89 Volume 2,546,600
Day high $2.06 Avg. volume 2,787,592
50-day MA $3.16 Dividend yield N/A
200-day MA $5.05 Market Cap 216.05M

CHRS Stock Price Chart Interactive Chart >


  • Growth is the dimension where CHRS ranks best; there it ranks ahead of 83.8% of US stocks.
  • The strongest trend for CHRS is in Growth, which has been heading up over the past 177 days.
  • CHRS's current lowest rank is in the Stability metric (where it is better than 0.72% of US stocks).

CHRS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CHRS is -1.58 -- better than merely 4.81% of US stocks.
  • CHRS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.25% of US stocks.
  • COHERUS BIOSCIENCES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -45.41%, greater than the shareholder yield of merely 11.05% of stocks in our set.
  • Stocks that are quantitatively similar to CHRS, based on their financial statements, market capitalization, and price volatility, are NSPR, TARS, SERA, VLCN, and CLPT.
  • Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to

CHRS Valuation Summary

  • In comparison to the median Healthcare stock, CHRS's price/sales ratio is 47.22% lower, now standing at 1.9.
  • CHRS's EV/EBIT ratio has moved up 1.2 over the prior 109 months.

Below are key valuation metrics over time for CHRS.

Stock Date P/S P/B P/E EV/EBIT
CHRS 2023-11-03 1.9 -2.0 -1.3 -3.3
CHRS 2023-11-02 1.7 -1.8 -1.2 -3.1
CHRS 2023-11-01 1.7 -1.7 -1.1 -3.1
CHRS 2023-10-31 1.7 -1.8 -1.2 -3.2
CHRS 2023-10-30 1.6 -1.6 -1.1 -3.0
CHRS 2023-10-27 1.4 -1.4 -0.9 -2.9

CHRS Growth Metrics

    The year over year revenue growth rate now stands at -31.41%.
  • Its year over year net income to common stockholders growth rate is now at -175.63%.
  • The 2 year cash and equivalents growth rate now stands at 68.53%.
Over the past 67 months, CHRS's revenue has gone up $61,153,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 239.061 -193.493 -278.609
2022-06-30 276.14 -142.693 -230.487
2022-03-31 303.632 -92.844 -210.237
2021-12-31 326.551 -37.432 -287.1
2021-09-30 363.599 48.014 -231.667
2021-06-30 394.647 81.656 -165.206

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
  • CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.513 0.886 -0.228
2021-03-31 0.572 0.913 -0.075
2020-12-31 0.664 0.921 0.250
2020-09-30 0.803 0.931 0.332
2020-06-30 0.995 0.936 0.477
2020-03-31 1.206 0.950 0.576

CHRS Price Target

For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.71 Average Broker Recommendation 1.57 (Moderate Buy)

Coherus BioSciences, Inc. (CHRS) Company Bio

Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.

CHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream

Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about COHERUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Why Coherus BioSciences Was Plummeting This Week

A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Market Intelligence, the healthcare company's share price had fallen by a steep 56% week to date. On Monday after market close, Coherus unveiled a set of third-quarter results that, despite a double-digit revenue increase, missed analyst estimates.

Yahoo | November 10, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

William White on InvestorPlace | November 7, 2023

Why Coherus Biosciences Stock Dropped Today

Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance. It generated $40 million of net sales of Cimerli, which treats retinal conditions -- up 50% from the prior quarter -- and $1.4 million from arthritis treatment Yusimry. Coherus highlighted its recently resubmitted biologic license application for Udenyca OnBody, its on-body injector presentation of Udenyca, after the completion and satisfactory resolution of a Food and Drug Administration (FDA) review of inspection findings at a third-party filler.

Yahoo | November 7, 2023

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be […]

Yahoo | November 7, 2023

Q3 2023 Coherus BioSciences Inc Earnings Call

Q3 2023 Coherus BioSciences Inc Earnings Call

Yahoo | November 7, 2023

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo -26.52%
3-mo -62.98%
6-mo -52.10%
1-year -69.88%
3-year -89.58%
5-year -81.99%
YTD -75.51%
2022 -50.38%
2021 -8.17%
2020 -3.47%
2019 98.95%
2018 2.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!